BACKGROUND: Few data are published on docetaxel toxicity in obese patients. PATIENTS AND METHODS: All obese patients (n=100) treated for early breast cancer during three consecutive years at our Institution, were retrospectively investigated. The same number of non-obese patients was randomly selected and used as controls. We assessed the factors predictive of the relative dose intesity (RDI) reduction, including body composition. RESULTS: A total of 18% (n=18) of obese patients and 5% (n=5) of non-obese patients required reduction of docetaxel RDI due to toxicity (p=0.008). In a multivariate analysis, body mass index (BMI) and age were predictive of a reduction in RDI. Among the 89 patients with a determination of body composition, patients with a higher fat mass more frequently had a reduction in docetaxel RDI (p=0.002). In multivariate analysis, fat mass was the only independent factor predictive of a reduction in docetaxel RDI. CONCLUSION: Obese patients treated for early breast cancer more frequently required a reduction in docetaxel RDI. Fat mass seems to be the best factor predictive of a reduction in docetaxel RDI.
BACKGROUND: Few data are published on docetaxeltoxicity in obesepatients. PATIENTS AND METHODS: All obesepatients (n=100) treated for early breast cancer during three consecutive years at our Institution, were retrospectively investigated. The same number of non-obesepatients was randomly selected and used as controls. We assessed the factors predictive of the relative dose intesity (RDI) reduction, including body composition. RESULTS: A total of 18% (n=18) of obesepatients and 5% (n=5) of non-obesepatients required reduction of docetaxel RDI due to toxicity (p=0.008). In a multivariate analysis, body mass index (BMI) and age were predictive of a reduction in RDI. Among the 89 patients with a determination of body composition, patients with a higher fat mass more frequently had a reduction in docetaxel RDI (p=0.002). In multivariate analysis, fat mass was the only independent factor predictive of a reduction in docetaxel RDI. CONCLUSION:Obesepatients treated for early breast cancer more frequently required a reduction in docetaxel RDI. Fat mass seems to be the best factor predictive of a reduction in docetaxel RDI.
Entities:
Keywords:
Early breast cancer; docetaxel; dose intensity; fat mass; obesity; toxicity
Authors: Ki-Yong An; Fernanda Z Arthuso; Dong-Woo Kang; Andria R Morielli; Stephanie M Ntoukas; Christine M Friedenreich; Donald C McKenzie; Karen Gelmon; John R Mackey; Kerry S Courneya Journal: Breast Cancer Res Treat Date: 2021-03-29 Impact factor: 4.872